STOCK TITAN

Arcutis Biotherapeutics Inc - ARQT STOCK NEWS

Welcome to our dedicated news page for Arcutis Biotherapeutics (Ticker: ARQT), a resource for investors and traders seeking the latest updates and insights on Arcutis Biotherapeutics.

Our selection of high-quality news articles is accompanied by an expert summary from Rhea-AI, detailing the impact and sentiment surrounding the news at the time of release, providing a deeper understanding of how each news could potentially affect Arcutis Biotherapeutics's stock performance. The page also features a concise end-of-day stock performance summary, highlighting the actual market reaction to each news event. The list of tags makes it easy to classify and navigate through different types of news, whether you're interested in earnings reports, stock offerings, stock splits, clinical trials, fda approvals, dividends or buybacks.

Designed with both novice traders and seasoned investors in mind, our page aims to simplify the complex world of stock market news. By combining real-time updates, Rhea-AI's analytical insights, and historical stock performance data, we provide a holistic view of Arcutis Biotherapeutics's position in the market.

Rhea-AI Summary
Arcutis Biotherapeutics presents new data on roflumilast foam for the treatment of scalp and body psoriasis
Rhea-AI Impact
Rhea-AI Sentiment
End-of-Day
-- %
Tags
-
Rhea-AI Summary
Arcutis Biotherapeutics expands indication for ZORYVE cream for children with plaque psoriasis
Rhea-AI Impact
Rhea-AI Sentiment
End-of-Day
5.87%
Tags
-
Rhea-AI Summary
Arcutis Biotherapeutics grants inducement awards to new Chief Commercial Officer and newly hired employees
Rhea-AI Impact
Rhea-AI Sentiment
End-of-Day
5.87%
Tags
none
Rhea-AI Summary
Arcutis Biotherapeutics appoints Todd Edwards as Chief Commercial Officer (CCO) and promotes Ayisha Jeter to Senior Vice President, Marketing and Market Access
Rhea-AI Impact
Rhea-AI Sentiment
End-of-Day
-6.17%
Tags
management
-
Rhea-AI Summary
Arcutis Biotherapeutics launches educational campaign for seborrheic dermatitis
Rhea-AI Impact
Rhea-AI Sentiment
End-of-Day
7.43%
Tags
none
-
Rhea-AI Summary
Arcutis Biotherapeutics announced positive results from the INTEGUMENT-PED pivotal Phase 3 trial of roflumilast cream 0.05% for pediatric atopic dermatitis. 25.4% of children achieved IGA Success compared to 10.7% with vehicle. Roflumilast cream also showed significant improvements in EASI-75 and itch reduction. The study reinforces the safety and efficacy profile of roflumilast cream. The company plans to submit an sNDA for the treatment of children ages 2 to 5 years.
Rhea-AI Impact
Rhea-AI Sentiment
End-of-Day
1.56%
Tags
Rhea-AI Summary
Arcutis Biotherapeutics grants 39,000 restricted stock units to new employees
Rhea-AI Impact
Rhea-AI Sentiment
End-of-Day
-- %
Tags
none
-
Rhea-AI Summary
Arcutis Biotherapeutics submits sNDA for roflumilast cream for the treatment of atopic dermatitis
Rhea-AI Impact
Rhea-AI Sentiment
End-of-Day
5.13%
Tags
none
-
Rhea-AI Summary
Arcutis Biotherapeutics announces positive results from long-term study of roflumilast cream for atopic dermatitis
Rhea-AI Impact
Rhea-AI Sentiment
End-of-Day
-2.32%
Tags
none
Rhea-AI Summary
Arcutis Biotherapeutics to participate in Morgan Stanley 21st Annual Global Healthcare Conference
Rhea-AI Impact
Rhea-AI Sentiment
End-of-Day
-6.4%
Tags
conferences
Arcutis Biotherapeutics Inc

Nasdaq:ARQT

ARQT Rankings

ARQT Stock Data

1.16B
74.79M
2.5%
95.84%
16.75%
Pharmaceutical Preparation Manufacturing
Manufacturing
Link
United States
Westlake Village

About ARQT

arcutis biotherapeutics, inc., a biopharmaceutical company, focuses on developing and commercializing treatments for dermatological diseases. its lead product candidate is arq-151, a topical cream formulation of roflumilast that is in phase iii clinical trials for the treatment of plaque psoriasis and atopic dermatitis. the company is also developing arq-154, a topical foam formulation of arq-151 for the treatment of seborrheic dermatitis and scalp psoriasis; arq-252, a selective topical small molecule inhibitor of janus kinase type 1 for hand eczema and other inflammatory dermatoses; and arq-255, a topical formulation of arq-252 designed to reach deeper into the skin to the postulated site of inflammation in alopecia areata. the company was formerly known as arcutis, inc. and changed its name to arcutis biotherapeutics, inc. in october 2019. arcutis biotherapeutics, inc. was founded in 2016 and is headquartered in westlake village, california.